BRIEF-Exxonmobil Appointed Maria Dreyfus To Board-January 2024-www.financetom.com

BRIEF-Exxonmobil Appointed Maria Dreyfus To Board

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Exxonmobil Appointed Maria Dreyfus To Board

May 3, 2024 6:41 AM

May 3 (Reuters) - Pioneer Natural Resources Co ( PXD ):

* EXXONMOBIL ( XOM ): IN CONNECTION WITH MERGER AGREEMENT, COMPANY

INCREASED SIZE OF COMPANY'S BOARD OF DIRECTORS BY ONE MEMBER

* EXXONMOBIL ( XOM ): APPOINTED MARIA S. DREYFUS TO COMPANY'S BOARD

DIRECTORS

* EXXONMOBIL ( XOM ): IN ACCORDANCE WITH FTC CONSENT ORDER IN

CONNECTION

WITH MERGER, SCOTT D. SHEFFIELD WILL NOT JOIN COMPANY'S BOARD

Source text for Eikon:

Further company coverage:

Previous page： Integrated Electrical Services Fiscal Q3 Adjusted Earnings, Revenue Climb; Board Approves $200 Million Buyback Next page： FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Integrated Electrical Services Fiscal Q3 Adjusted Earnings, Revenue Climb; Board Approves $200 Million Buyback

Aug 2, 2024

08:42 AM EDT, 08/02/2024 (MT Newswires) -- Integrated Electrical Services (IESC) reported fiscal Q3 adjusted earnings Friday of $2.67 per diluted share, up from $1.08 a year earlier. Revenue for the quarter ended June 30 was $768.4 million, up from $584.4 million a year earlier. Analysts' estimates were not readily available for comparison. The company also said its board has...

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade

Aug 2, 2024

Thursday, the FDA approved Adaptimmune Therapeutics ( ADAP ) plc’s Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma, a rare type of cancer that tends to occur near large joints, mainly the knees. The approval covers patients who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen. This indication is approved under...

Twist Bioscience Fiscal Q3 Loss Widens, Revenue Rises; Lifts Revenue Outlook for Fiscal Q4, 2024

Aug 2, 2024

08:36 AM EDT, 08/02/2024 (MT Newswires) -- Twist Bioscience ( TWST ) reported a fiscal Q3 loss Friday of $1.47 per diluted share, widening from a loss of $1.01 a year earlier. Analysts polled by Capital IQ expected a per-share loss of $0.77. Revenue for the quarter ended June 30 was $81.5 million, up from $63.7 million a year earlier....

ArcBest Q2 Non-GAAP Net Income Rises, Revenue Falls

Aug 2, 2024

08:39 AM EDT, 08/02/2024 (MT Newswires) -- ArcBest ( ARCB ) reported Q2 non-GAAP net income Friday of $1.98 per diluted share, up from $1.54 a year earlier. Analysts polled by Capital IQ expected $2.06. Revenue for the quarter ended June 30 was $1.08 billion, down from $1.10 billion a year earlier. Analysts surveyed by Capital IQ expected $1.06 billion....